Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
Nature Medicine|June 23, 2022
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinomaAndrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, et al.
The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
Cell Host & Microbe|August 1, 2023
Rational design of a booster vaccine against COVID-19 based on antigenic distanceYe-Fan Hu, Terrence Tsz-Tai Yuen, Hua-Rui Gong, et al.
Hepatobiliary Surgery and Nutrition|June 23, 2023
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021Tan-To Cheung, Simon Chun-Ho Yu, Stephen L Chan, et al.
Disease Markers|August 9, 2014
The clinicopathological significance of miR-133a in colorectal cancerTimothy Ming-Hun Wan, Colin Siu-Chi Lam, Lui Ng, et al.
Liver Cancer|May 29, 2015
Hong Kong consensus recommendations on the management of hepatocellular carcinomaRonnie Tung-Ping Poon, Tom Tan-To Cheung, Philip Chong-Hei Kwok, et al.
The Lancet. Gastroenterology & Hepatology|February 16, 2024
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 studyThomas Yau, Ahmed Kaseb, Ann-Lii Cheng, et al.
JAMA Oncology|October 1, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical TrialThomas Yau, Yoon-Koo Kang, Tae-You Kim, et al.
Liver Cancer|October 30, 2023
Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized TrialsDarren Jun Hao Tan, Ansel Shao Pin Tang, Wen Hui Lim, et al.
Pageof 14